Joseph McCracken S.'s most recent trade in Savara Inc was a trade of 10,000 Common Stock done at an average price of $2.1 . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Savara Inc | Joseph S. McCracken | Director | Purchase of securities on an exchange or from another person at price $ 2.08 per share. | 29 May 2025 | 10,000 | 260,837 (0%) | 0% | 2.1 | 20,825 | Common Stock |
| Savara Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 40,000 | 250,837 (0%) | 0% | 0 | Common Stock | |
| Savara Inc | Joseph S. McCracken | Director | Purchase of securities on an exchange or from another person at price $ 2.95 per share. | 19 Nov 2024 | 20,000 | 210,837 (0%) | 0% | 3.0 | 59,072 | Common Stock |
| Lumos Pharma Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 3,328 | 3,328 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Joseph McCracken S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 22,500 | 190,837 (0%) | 0% | 0 | Common Stock | |
| Lumos Pharma Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 3,345 | 3,345 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Joseph S. McCracken | Director | Purchase of securities on an exchange or from another person at price $ 8.60 per share. | 25 Aug 2022 | 3,170 | 11,721 (0%) | 0% | 8.6 | 27,262 | Common Stock |
| Lumos Pharma Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 3,431 | 3,431 | - | - | Stock Option (Right to Buy) | |
| Savara Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Joseph S. McCracken | Director | Purchase of securities on an exchange or from another person at price $ 7.55 per share. | 11 Aug 2021 | 7,475 | 8,551 (0%) | 0% | 7.5 | 56,406 | Common Stock |
| Lumos Pharma Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 2,910 | 2,910 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 367 | 1,076 (0%) | 0% | 0 | Common Stock | |
| Savara Inc | Joseph S. McCracken | Director | Purchase of securities on an exchange or from another person at price $ 1.45 per share. | 15 Mar 2021 | 68,965 | 168,337 (0%) | 0% | 1.4 | 99,999 | Common Stock |
| Savara Inc | Joseph S. McCracken | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) |